Most, however, were supportive and argued Palforiza met the standards for approval. Insurer coverage is also a question. The Institute for Clinical and Economic Review, a non-profit that measures the cost effectiveness of drugs, said Palforzia would push healthcare spending above its budget impact threshold if priced at an assumed cost of $4,200 per year. Only 41% of eligible patients would be able to take Palforzia while keeping spending below the group's $990 million budget ceiling. Aimmune is considering pricing Palforzia, if approved, at a cost between $3,000 and $20,000, according to a recent company presentation. ICER's own advisors, called the California Technology Assessment Forum, voted 12-4 that the net health benefit of Palforzia and avoidance had not been proven superior to avoidance alone. That organization was also asked to assess DBV's patch product, called Viaskin Peanut. A similar negative 12-4 vote was cast on its net health benefit.